Brentuximab vedotin is an antibody-drug conjugate targeting CD30 and is currently US Food and Drug Administration (FDA) approved for patients with Hodgkin lymphoma who are post-autologous hematopoietic stem cell transplant with high risk for relapse [30]. The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.